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Controlled ATP release has been demonstrated from many neuronal and non-neuronal cell
types. Once released, extracellular ATP acts on cells in a paracrine manner via purinergic
receptors. Considerable evidence now suggests that extracellular nucleotides, signaling
via P2 receptors, play important roles in bone homeostasis modulating both osteoblast
and osteoclast function. In this study, we demonstrate that mouse osteoclasts and their
precursors constitutively releaseATP into their extracellular environment. Levelswere high-
est at day 2 (precursor cells), possibly reﬂecting the high number of red blood cells and
accessory cells present. Mature osteoclasts constitutively released ATP in the range 0.05–
0.5 pmol/ml/cell. Both osteoclasts and osteoblasts expressmRNA and protein for the P2X7
receptor.We found that in osteoclasts, expression levels are fourfold higher in mature cells
relative to precursors, whilst in osteoblasts expression remains relatively constant during
differentiation. Selective antagonists (0.1–100μMAZ10606120, A438079, and KN-62) were
used to determine whether this release was mediated via P2X7 receptors. AZ10606120,
A438079, and KN-62, at 0.1–10μM, decreased ATP release by mature osteoclasts by up to
70, 60, and 80%, respectively. No differences in cell viability were observed. ATP release
also occurs via vesicular exocytosis; inhibitors of this process (1–100μM NEM or brefeldin
A) had no effect on ATP release from osteoclasts. P2X7 receptor antagonists (0.1–10μM)
also decreased ATP release from primary rat osteoblasts by up to 80%. These data show
that ATP release via the P2X7 receptor contributes to extracellular ATP levels in osteo-
clast and osteoblast cultures, suggesting an important additional role for this receptor in
autocrine/paracrine purinergic signaling in bone.
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INTRODUCTION
The idea that purines act as extracellular signaling molecules was
ﬁrst suggested in 1929, yet it was not until 1972 that the con-
cept of purinergic neurotransmission was proposed (Burnstock,
1972). It is now widely accepted that extracellular nucleotides,
signaling via the P2 receptors, participate in a wide number of bio-
logical processes in both neuronal and non-neuronal tissues. P2
receptors are subdivided into the P2X ligand-gated ion channels
and P2Y G-protein-coupled receptors (Kennedy and Burnstock,
1985; Abbracchio and Burnstock, 1994). Currently, seven P2X
receptors (P2X1-7) and eight P2Y (P2Y1,2,4,6,11,12,13,14) receptors
have been identiﬁed; each of these receptors has been cloned,
characterized, and displays distinct tissue expression and phar-
macology (Ralevic and Burnstock, 1998; Burnstock, 2007). P2
receptors respond to a range of adenine and uridine-containing
nucleotides including adenosine triphosphate (ATP), adenosine
diphosphate (ADP), uridine triphosphate (UTP), and uridine
diphosphate (UDP).
In recent years, it has become evident that extracellular
nucleotides play a signiﬁcant role in bone biologymodulating both
osteoblast and osteoclast function (see reviews by Grol et al., 2009;
Orriss et al., 2010). Expression of multiple P2 receptor subtypes
by osteoblasts (Maier et al., 1997; Hoebertz et al., 2000; Nakamura
et al., 2000; Gartland et al., 2001; Ke et al., 2003; Ihara et al., 2005;
Orriss et al., 2006, 2010; Alqallaf et al., 2009) and osteoclasts has
nowbeen reported (Bowler et al., 1995;Naemsch et al., 1999; Buck-
ley et al., 2002; Gartland et al., 2003a; Korcok et al., 2005; Orriss
et al., 2010, 2011b). Functional effects of purinergic signaling on
bone cells include increased osteoblast proliferation (Nakamura
et al., 2000), decreased bone mineralization by osteoblasts (Orriss
et al., 2007), the modulation of osteoblast responses to systemic
factors such as parathyroid hormone (Bowler et al., 2001; Buck-
ley et al., 2001), induction of osteoblastic membrane blebbing
(Panupinthu et al., 2007), and the production of lipid mediators
(Panupinthu et al., 2008). In osteoclasts, activation of the P2Y1
and P2Y6 receptor subtypes has been shown to enhance forma-
tion, activity, and survival (Hoebertz et al., 2001; Korcok et al.,
2005; Orriss et al., 2011b). The P2X7 receptor, which has a more
complex role in osteoclast function, has been implicated in cell
fusion (Gartland et al., 2003b), apoptosis (Penolazzi et al., 2005),
the translocation, and activation of NFκB (nuclear factor kappa-
light-chain-enhancer of activated B cells; Korcok et al., 2004) and
PKC (Armstrong et al., 2009) and intercellular communication
(Jorgensen et al., 2002). The important role of P2 receptors in
bone homeostasis is further highlighted by the recent studies of
several knockout mouse models (P2Y1, P2Y2, P2Y6, P2X7), all
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of which show signiﬁcant changes in bone architecture and cell
function (reviewed by Orriss et al., 2011a).
ATP is present in cell cytoplasm at concentrations between
2 and 5mM. Following membrane damage or necrosis, all cells
can potentially release ATP into the extracellular environment,
which can then act in an autocrine/paracrine manner to inﬂu-
ence local purinergic signaling. In addition, numerous excitatory
and non-excitatory cells including epithelial and endothelial cells
(Bodin and Burnstock, 2001; Knight et al., 2002), platelets (Beigi
et al., 1999), ﬁbroblasts (Gerasimovskaya et al., 2002), chondro-
cytes (Graff et al., 2000), erythrocytes (Sprague et al., 1998), and
astrocytes (Coco et al., 2003) release ATP in a controlled man-
ner. Constitutive ATP release has also been reported from primary
osteoblasts (Orriss et al., 2009), a number of osteoblast-like cells
lines (Romanello et al., 2001; Buckley et al., 2003; Genetos et al.,
2005) and MLO-Y4 osteocyte-like cells (Genetos et al., 2007;
Thompson et al., 2011). Controlled release of ATP from mature
osteoclasts has not been described.
Cellular release of ATP is thought to occur via several mech-
anisms including (1) ATP binding cassette (ABC) transporters
(Lazarowski et al., 2003), (2) vesicular exocytosis, perhaps involv-
ing lysosomes (Zhang et al., 2007), (3) gap junctions, connections,
and/or pannexin hemichannels (Lazarowski et al., 2003; Spray
et al., 2006), and (4) the P2X7 receptor (Suadicani et al., 2006).
Several ABC proteins are potential candidates for mediating ATP
release including the cystic ﬁbrosis transmembrane conductance
regulator (CFTR). The CFTRwas initially thought tomediate ATP
release from several cell types including erythrocytes (Sprague
et al., 1998); however, later work indicated that the CFTR regu-
lates rather than mediates the release of ATP (Sugita et al., 1998;
Watt et al., 1998; Braunstein et al., 2001). Controlled vesicu-
lar exocytosis is implicated in ATP release from many cell types
including epithelial and endothelial cells (Bodin and Burnstock,
2001; Knight et al., 2002). Additionally, it has been suggested that
ATP release from osteoblasts occurs, at least in part, via vesic-
ular mechanisms (Genetos et al., 2005; Romanello et al., 2005;
Orriss et al., 2009). Connexin hemichannels and gap junctions,
which allow the movement of molecules less than 1 kDa, report-
edly act as a conductive pathway to mediate ATP release from
astrocytes (Cotrina et al., 1998; Bowler et al., 2001; Coco et al.,
2003).
The P2X7 receptor is distinct from other P2X receptors in that
it has a relatively low sensitivity for ATP (>100μM) and pref-
erentially binds to 2′,3′-O-(benzoyl-4-benzoyl)-ATP (Bz-ATP).
Prolonged or repeated exposure to high concentrations of P2X7
agonist mediates the formation of cytolytic pores (Murgia et al.,
1992), whereas, transient receptor stimulation causes the forma-
tion of non-selective membrane pores permeable to molecules up
to 900 kDa in size (Di Virgilio, 1995). Recently, involvement of
the P2X7 receptor in ATP release has been reported in astrocytes
(Suadicani et al., 2006) and osteoclast monocyte precursors (Pel-
legatti et al., 2011). In osteoclast precursors, the release of ATP via
the P2X7 receptor is thought to be an important source of extracel-
lular adenosine which acts to promote cell fusion (Pellegatti et al.,
2011).
The aims of this study were to investigate (1) whether osteo-
clasts release ATP under normal conditions, (2) the effect of
osteoclast differentiation on constitutive ATP release, and (3) the
role of the P2X7 receptor in the release of ATP from bone cells.
MATERIALS AND METHODS
REAGENTS
All tissue culture reagents were purchased from Gibco (Pais-
ley, UK). Unless otherwise mentioned, all chemicals were pur-
chased from Sigma Aldrich (Poole, Dorset, UK). The CytoTox
96® non-radioactive cytotoxicity assay and CellTiter-Glo® lumi-
nescent assay were obtained from Promega UK (Southampton,
UK). The P2X7 receptor antagonists were purchased from Tocris
Bioscience (Bristol, UK). All molecular biology reagents were pur-
chased from Invitrogen (Paisley, UK) and all primers from MWG
Biotech (Ebersberg, Germany).
CELL CULTURE
Primary rat osteoblast cells were obtained from the calvaria of 2-
day-old neonatal Sprague-Dawley rats and cultured as described
previously (Orriss et al., 2012). Osteoclasts were isolated from
the long bones of two 6-week-old mice and cultured as we have
previously reported (Orriss and Arnett, 2012).
MEASUREMENT OF ATP RELEASE
Prior to measurement of ATP release, culture medium was
removed, cell layers washed, and cells incubated with serum-free
DMEM(osteoblasts: 1ml/well) orMEM(osteoclasts: 250μl/well).
Samples were collected after 1 h and immediately snap-frozen on
dry ice for later ATP quantiﬁcation. In the experiments examining
release mechanisms, P2X7 receptor antagonists (1 nM–100μM
AZ10606120, KN-62,A438079,A740003), and vesicular inhibitors
[0.1–50μMbrefeldin A, n-ethylmaleimide (NEM)] were added to
the serum-free DMEM. ATP release was measured luminetrically
using the luciferin–luciferase assay as described previously (Orriss
et al., 2009).
CELL PROLIFERATION AND VIABILITY ASSAY
Cell number and viability was determined in all samples using
the CytoTox 96® colorimetric cytotoxicity assay (Promega UK,
Southampton, UK). This assay quantiﬁes cellular lactate dehy-
drogenase (LDH), a stable cytosolic enzyme that is released on
cell lysis. LDH oxidizes lactate into pyruvate, generating NADH,
which is then used to convert a tetrazolium salt into a red formazan
product in proportion to the number of lysed cells.
Following measurement of ATP release, cell supernatants were
collected to determine medium LDH levels (cell viability). To
establish total cellular LDH levels, cells were lysed with 1% Tri-
ton X-100 in water (lysis buffer, 15μl/ml of medium) for 1 h. The
LDH content of the supernatants and cell lysates were measured
colorimetrically (490 nm; ELX800 plate reader, Bio-tek Interna-
tional) as per manufacturer’s instructions. A standard curve for
determination of cell numbers was constructed using cells seeded
at 102–106/well. Manual cell counts were performed in parallel for
assay validation. By expressing medium LDH as a percentage of
the total cellular LDH cell viability could be also calculated.
QUINACRINE STAINING
The acridine derivative, quinacrine, is a weak base that binds ATP
with a high afﬁnity. When excited by light at 476 nm it ﬂuoresces
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in the 500- to 540-nm range and is widely used to visualize
ATP-containing subcellular compartments in live cells (Irvin and
Irvin, 1954; Olson et al., 1976). Osteoblasts and osteoclasts were
seeded onto sterile 1 cm diameter disks, cut from Melinex (Du
Pont Teijin Films, Dumfries, UK) clear polyester ﬁlm, in 24-well
trays at 2.5× 104 cells/disk and 106 cells/disk, respectively, and
cultured until the formation of mature cells. To visualize ATP-
ﬁlled vesicles, Melinex disks were twice washed with PBS before
incubation with 30μM quinacrine for 1 h; disks were washed
twice more and mounted onto microscope slides. The cells were
immediately observed using ﬂuorescence microscopy with a digi-
tal camera attachment (AxioCam MRC5, Imaging Associates Ltd.,
Bicester, UK).
TOTAL RNA EXTRACTION AND DNase TREATMENT
Osteoclasts were cultured on large dentine disks in 24-well trays
and total RNA extracted at 2, 5, 7, and 9 days of culture using TRI-
ZOL® reagent (Invitrogen, Paisley,UK) according to themanufac-
turer’s instructions. Extracted RNA was treated with RNase-free
DNase I (35U/ml) for 30min at 37˚C. The reactionwas terminated
by heat inactivation at 65˚C for 10min. Total RNA was quantiﬁed
spectrophotometrically bymeasuring absorbance at 260 nM. RNA
was stored at –80˚C until ampliﬁcation by qPCR.
QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION (qPCR)
Osteoclast RNA (50 ng) was transcribed and ampliﬁed using the
iScript one-step qRT-PCR kit with SYBR green (Bio-rad Labora-
tories Ltd., Hemel Hempstead, UK), which allows cDNA synthesis
and PCR ampliﬁcation to be carried out sequentially. qRT-PCR
was performed according to the manufacturer’s instructions, with
initial cDNA synthesis (50˚C for 10min) and reverse transcriptase
inactivation (95˚C for 5min), followed by 40 cycles of denatura-
tion (95˚C for 10 s) and detection (60˚C for 30 s). Gene expression
was investigated in cells cultured for 2, 5, 7, and 9 days. Data were
analyzed using the Pfafﬂ method and are shown as changes in the
level of gene expression relative to that in precursor cells. All reac-
tions were carried out in triplicate using RNAs derived from four
different osteoclast cultures. Primer sequences: B actin S: gat ctg
gca cca cac ctt ct/AS: ggg gtg aag gtc tca aa; P2X7 S: ggc act gga gga
aaa ttt ga/AS: tga gca agt caa tgc aca ca.
WESTERN BLOT
Osteoclasts were cultured for 9 days and protein was extracted
at 2, 5, 7, and 9 days. Cell layers were lysed in ice-cold radio-
immunoprecipitation (RIPA) lysis buffer (50mM Tris–HCl pH
7.4, 150mM NaCl, 5mM EDTA, 0.1% SDS 1mM phenyl methyl
sulfonyl ﬂuoride (PMSF), 1mg/ml aprotinin, 1mM Na3VO4,
and 2.5mg/ml deoxycholic acid). Cell homogenates were soni-
cated for 5min and stored at −80˚C for at least half an hour
before use. Protein concentrations from lysates were determined
using the Bradford assay (Sigma Aldrich, Gillingham, Dorset,
UK). Prior to loading total protein samples were denatured by
incubating at 95˚C for 5min in the presence of 5× reducing
sample buffer (60mM Tris–HCl pH 6.8, 25% glycerol, 2% SDS,
10% β-mercaptoethanol, and 0.1% bromophenol blue). Protein
samples (30μg/lane) were loaded into SDS-PAGE (10%) gels and
transferred onto a polyvinyldiﬂuoride (PVDF)membrane (Amer-
sham, Buckinghamshire, UK) by the use of a wet tank blotter
(Bio-Rad, Hercules, CA, USA) at 150V for 1 h. Membranes were
then blocked with 5% non-fat milk and incubated with the P2X7
(1:200) antibody overnight at room temperature (P2X7 extra-
cellular, Alomone, Jerusalem, Israel). After washing, blots were
incubated in horseradish peroxidase-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Inc.,West Grove,
PA, USA) for 1 h at room temperature. A peroxidase detection
system (Immobilon™Western, Millipore UK, Watford, UK) was
used for the visualization of the immunoreactivity. Western blot-
ting performed in the presence of an antibody-speciﬁc blocking
peptide or without primary antibody served as negative controls.
Membranes were subsequently stained with ponceau red to ensure
equal loading of the protein.
STATISTICAL ANALYSIS
Statistical comparisons weremade by one-way analysis of variance
and adjusted using theBonferronimethod. Representative data are
presented as means± SEM for 6–12 replicates. Results presented
are for representative experiments that were each repeated at least
three times.
RESULTS
CONSTITUTIVE ATP RELEASE FROM BONE CELLS
Controlled ATP release from osteoblasts has been reported by
many groups (Romanello et al., 2001; Buckley et al., 2003; Gene-
tos et al., 2005). We have shown previously that ATP release from
osteoblasts occurs, at least in part, by vesicular exocytosis (Orriss
et al., 2009). Baseline results conﬁrmed that osteoblasts consti-
tutively release ATP in the range 0.5–8 pmol/ml/cell (Figure 1A).
Furthermore, the amount of ATP released was increased up to
12-fold in differentiating osteoblasts (day 7 and 10) and 16-fold
in mature, bone-forming osteoblasts (day 14) relative to precur-
sor cells (day 4). Cell viability remained constant throughout
the culture period (Figure 1A). In mature osteoblasts, abundant
cytoplasmic quinacrine staining, with a clear granular–vesicular
appearance was observed, indicating the presence of intracellular
ATP stores (Figures 1C,D). Widespread quinacrine staining was
also evident in precursor cells and differentiating osteoblasts (not
shown).
We found that osteoclasts also constitutively released ATP
throughout the culture period (Figure 1B). The levels detected
were up to 10-fold lower than osteoblasts, typically in the range
0.05–0.5 pmol/ml/cell. The highest levels of extracellularATPwere
detected in early-stage cultures of precursor cells (day 2), possibly
reﬂecting some initial cell damage during the isolation procedure
and the high number of red blood cells present at this stage. The
amount of ATP release per cell did not appear to change during
osteoclastogenesis,with release fromearly osteoclasts (day 5) being
the same as from mature, resorbing osteoclasts (day 9; Figure 1B).
Quinacrine staining indicated the presence of abundant ATP in
the cytosol of mature osteoclasts (Figures 1E,F).
EXPRESSION OF THE P2X7 RECEPTOR BY OSTEOCLASTS
We have previously demonstrated expression of the P2X7 recep-
tor by primary rat osteoblasts (Orriss et al., 2006) and mouse
osteoclasts (Orriss et al., 2011b). We observed that P2X7 receptor
mRNA expression increased fourfold in mature, non-resorbing
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FIGURE 1 | Constitutive ATP release from bone cells. (A) Osteoblasts
released ATP constitutively throughout the culture period, with peak release
from mature, bone-forming cells (day 14); cell viability remained similar at
every stage of development. (B) Osteoclasts also constitutively released ATP
throughout the culture period. The highest level of ATP release was detected
from precursor cells (day 2), although this was accompanied by higher LDH
levels indicating a reduced cell viability. The amount of ATP release from early
osteoclasts (day 5) was the same as mature, resorbing cells (day 9). Values
are means±SEM (n =10–12 replicate wells or disks), signiﬁcantly different
from controls: *p<0.05, **p<0.01, ***p<0.001. Quinacrine staining
showing intracellular ATP in the cytosol of (C) osteoblasts, and (E)
osteoclasts, scale bars=10μm. Clear, granular staining shows ATP is
probably localized to vesicles in (D) a single osteoblast, and (F) a single
osteoclast, scale bars=2.5μm.
FIGURE 2 | Expression of the P2X7 receptor by osteoclasts. (A) Levels of
P2X7 mRNA were increased fourfold in mature osteoclasts relative to
precursor cells. Osteoclast activation by acid caused levels of the P2X7
receptor to be decreased in resorbing cells (day 9) compared to mature
non-activated cells (day 7). (B) P2X7 receptor protein was not detected in
precursor cells or early osteoclasts but was present in mature cells. Unlike
the mRNA, no differences in protein level were detected between mature and
mature, resorbing cells.
osteoclasts relative to precursor cells (Figure 2A). When mature
osteoclasts were activated to resorb by acid, P2X7 receptor expres-
sion decreased slightly, although still remaining 2.5-fold higher
than in precursor cells. Expression of P2X7 protein was not
detected in precursor cells or early osteoclasts, but only in mature
osteoclasts (Figure 2B).
P2X7 RECEPTOR ANTAGONISTS BLOCK ATP RELEASE FROM
OSTEOCLASTS
To determine whether the P2X7 receptor mediates ATP release
from osteoclasts, mature cells (day 7) were incubated with four
different P2X7 receptor antagonists prior to measurement of
extracellular ATP levels. All four inhibitors, which block the P2X7
receptor via different mechanisms, reduced ATP release from
osteoclasts (Figure 3). AZ10606120, which acts as a negative
allosteric modulator of the P2X7 receptor, inhibited ATP release
by 80% at 1–10μM (Figure 3A). KN-62, a non-competitive P2X7
receptor antagonist, reduced ATP efﬂux by up to 90% in the con-
centration range 0.1–10μM (Figure 3B). A438079, a competitive
P2X7 receptor antagonist, decreased ATP release 70–80% at con-
centrations ≥0.1μM (Figure 3C). Finally, the potent, competitive
P2X7 receptor antagonist, A740003, inhibited ATP release up to
Frontiers in Endocrinology | Bone Research March 2012 | Volume 3 | Article 41 | 4
Brandao-Burch et al. ATP release and osteoclasts
85% at ≥1 nM (Figure 3D). For all four antagonists, treatment
with concentrations up to 10μM did not affect osteoclast viabil-
ity (Figures 3A–D); however, AZ10606120, KN-62, and A740003
at concentrations >10μM were toxic, causing signiﬁcant cell
death.
INHIBITORS OF VESICULAR EXOCYTOSIS DO NOT INFLUENCE ATP
RELEASE FROM OSTEOCLASTS
To determine whether ATP release from mature osteoclasts could
involve vesicular exocytosis, the cells were incubated with two
selective inhibitors, NEM and Brefeldin A, and the effects on
extracellular ATP levels measured. NEM, which inhibits vesicu-
lar fusion with the plasma membrane, and Brefeldin A, which
disrupts vesicular trafﬁcking by blocking protein transport from
the endoplasmic reticulum to the Golgi apparatus, inhibit ATP
release from osteoblasts by up to 80% at 100μM (Figure 4A).
No effect was seen at concentrations below 100μM. In contrast,
NEM (Figure 4B) and Brefeldin A (Figure 4C), had no effect on
ATP release from osteoclasts at concentrations up to 50μM.At the
concentrations tested, no effects of these inhibitors on cell viabil-
ity were observed. Concentrations of ≥100μM caused signiﬁcant
cell death in osteoclasts but not in osteoblasts.
P2X7 RECEPTOR ANTAGONISTS REDUCE ATP RELEASE FROM
OSTEOBLASTS
To determine whether the P2X7 receptor could contribute
toward ATP release from mature osteoblasts, the antagonists
AZ10606120,A438079, andA740003were tested at between 10 nM
and100μM; at these concentrations, no effects on cell viability
were observed. Treatment with ≥100 nM AZ10606120 decreased
ATP release by 65–80% (Figure 5A), whilst ≥10 nM A438079
reduced ATP levels by∼25% (Figure 5B). A740003, at concentra-
tions≥1μM,was also inhibitory,decreasingATP levels by 60–80%
(Figure 5C).
FIGURE 3 | P2X7 receptor antagonists inhibit ATP release from
osteoclasts. Cells were cultured on dentine disks for 7 days before the
effect of P2X7 receptor antagonists on ATP release from mature
osteoclasts was investigated. (A) AZ10606120, (B) KN-62, (C) A438079,
and (D) A740003 decreased ATP release by up to 80, 90, 80, and 85%,
respectively. At the concentrations shown no effects on cell viability
were observed. A740003 was the most potent of the P2X7 receptor
antagonists tested blocking ATP release from 1nM. Values are
means±SEM (n =10 replicate disks), signiﬁcantly different from
controls: ***p<0.001.
FIGURE 4 | Inhibitors of vesicular exocytosis do not block ATP release
from osteoclasts. (A) NEM and brefeldin A (100μM) inhibit ATP release from
mature osteoblasts by 80 and 40%, respectively. Cells were cultured on
dentine disks for 7 days before the effect vesicular exocytosis inhibitors on
ATP release from mature osteoclasts was investigated. (B) NEM and, (C)
brefeldin A had no effect on ATP release from osteoclasts. At the
concentrations shown no effects on cell viability were observed. Values are
means±SEM (n =10 replicate disks/wells).
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FIGURE 5 | P2X7 receptor antagonists decrease ATP release from
osteoblasts. Osteoblasts were cultured until the onset of bone formation
(∼10days) before the effect of P2X7 receptor antagonists on ATP release
was investigated. (A) AZ10606120, (B) A438079, and (C) A740003
decreased ATP release by up to 80, 25, and 80%, respectively. At the
concentrations shown no effects on cell viability were observed. Values
are means±SEM (n =12 replicate wells), signiﬁcantly different from
controls: *p<0.05, **p<0.01.
DISCUSSION
The aim of this investigation was to study controlled ATP release
from bone cells, particularly osteoclasts, and to determine the
mechanisms mediating this process. We demonstrated that osteo-
clasts contain extensive intracellular ATP stores and constitutively
release ATP in the range 0.05–0.5 pmol/ml/cell. Pharmacological
studies indicate that this efﬂux is primarilymeditated via the P2X7
receptor, rather than vesicular exocytosis. This constitutes the ﬁrst
report of controlled ATP release from mature, resorbing osteo-
clasts in vitro. In contrast, our earlier work has suggested that
osteoblasts release ATP principally by exocytosis (Orriss et al.,
2009). Here, however, we demonstrate that the P2X7 receptor also
contributes toward ATP efﬂux from osteoblasts.
ATP release was measured at all stages throughout the osteo-
clast culture, using cells grown on a natural, resorbable substrate
(dentine) over a 9-day period. At day 2 of culture, the majority of
cells present were precursors along with some residual red blood
cells from the bone marrow; by day 4 some of the cells exhibited
multinucleated osteoclast-like morphology; at day 7 mature, inac-
tive osteoclasts were observed, and by day 9, mature, resorbing
osteoclasts were present in acidiﬁed cultures as described recently
(Orriss et al., 2011b;Orriss andArnett, 2012).We found that osteo-
clasts constitutively released ATP at all times, although levels were
highest at the beginning of the culture period (day 2). This increase
in extracellular ATP levels was accompanied by a large decrease in
cell viability and is probably a consequence of the initial cell dam-
age during the isolation procedure. Thus, uncontrolled rather than
regulated, ATP release from damaged cells most likely artiﬁcially
enhanced the extracellular levels of ATP. Furthermore, since red
blood cells also release ATP (Sprague et al., 1998), the residual
erythrocytes seen in these cultures at day 2 could also have con-
tributed to the increased extracellular ATP levels seen at this stage.
By day 4 of culture there are no longer any red blood cells present
in these cultures.
Cellular differentiation did not affect basal ATP release in
osteoclast-forming cultures with early osteoclasts releasing sim-
ilar amounts to mature, resorbing cells. In contrast, ATP release
from osteoblasts is strongly dependent on differentiation, with
extracellular levels up to sevenfold higher in cultures of mature,
bone-forming cells relative to precursor cells (Orriss et al., 2009).
Differentiated osteoblasts have also been shown to have intra-
cellular ATP levels that are ﬁvefold higher than precursor cells
(Komarova et al., 2000). Thus, the increased ATP release from
mature osteoblasts could be a consequence of the higher intra-
cellular ATP concentration. In both cell types, the observed pat-
tern of quinacrine staining (used to visualize intracellular ATP)
was granular and cytoplasmic, suggesting a vesicular localization
of ATP.
Expression of the P2X7 receptor by bone cells has been widely
reported (see review by Grol et al., 2009). In this study, we con-
ﬁrmed the expression of the P2X7 receptor by primary mouse
osteoclasts. Furthermore, we demonstrated that expression lev-
els were dependent on differentiation, with the highest mRNA
and protein levels present in mature osteoclasts. This contrasts
to osteoblasts, where P2X7 receptor expression remains constant
throughout differentiation (Orriss et al., 2006).
In several cell types, the P2X7 receptor has been implicated as a
potential mechanism for the release of ATP (Suadicani et al., 2006;
Pellegatti et al., 2011). The role of the P2X7 receptor, polymor-
phisms of which have been associated with increased fracture risk
(Ohlendorff et al., 2007), in the regulation of bone cell function
is complex (Grol et al., 2009). This study investigated whether the
P2X7 receptor could mediate the release of ATP from bone cells.
A number of selective P2X7 receptor antagonists are commer-
cially available, each of which inhibits the receptor via a slightly
different pharmacological mechanism. All four of the antagonists
tested here (1 nM–1μMAZ10606120,KN-62,A438079,A740003)
reduced ATP release from mature osteoclasts by up to 90%, with-
out affecting cell viability. In contrast, the inhibitors of vesicular
exocytosis NEMand BrefeldinA had no effect onATP release from
osteoclasts. A previous study demonstrated that the P2X7 receptor
mediates the release of ATP from osteoclast monocyte precur-
sors (Pellegatti et al., 2011). Our investigation was performed on
mature osteoclasts rather than precursor cells but agrees with the
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ﬁndings of Pellegatti et al. (2011). Combined these data suggest
that efﬂux via the P2X7 receptor is the primarymechanism forATP
release from osteoclasts under normal conditions. However, since
none of the P2X7 receptor antagonists completely abolished ATP
efﬂux, it is possible that another pathway, such as gap junctions,
could also be involved.
Controlled ATP release from osteoblasts under normal condi-
tions has been widely reported (Romanello et al., 2001; Buckley
et al., 2003; Genetos et al., 2005; Orriss et al., 2009). Evidence
from these and our own studies suggests that vesicular exocytosis
is the major mechanism mediating ATP release from osteoblasts.
We previously demonstrated that inhibitors of vesicular exocytosis
reduced ATP release by up to 90% (Orriss et al., 2009). However,
the failure of these agents to completely block the process indi-
cated that anothermechanism could also be involved. In this study,
we have demonstrated that P2X7 receptor antagonists also block
ATP release from osteoblast by between 25 and 80%. The degree to
which these agents inhibitedATP efﬂuxwas quite variable between
experiments. This is most likely due to the heterogeneity of recep-
tor expression seen between different primary osteoblast isolations
and the observation that only a subset of osteoblasts express the
P2X7 receptor (Gartland et al., 2001). Thus not all osteoblasts will
have the ability to releaseATP via the P2X7 receptor. Consequently,
release from some cells will be unaffected by receptor antagonists.
Overall, our data suggest that efﬂux via the P2X7 receptor con-
tributes to the controlled release of ATP from osteoblasts but this
release is likely to be in addition to that which occurs via vesicular
exocytosis.
Exactly how activation of the P2X7 receptor mediates ATP
release from bone cells is unclear. Transient activation of the P2X7
receptor results in the formation of membrane pores permeable
to molecules up to 900 kDa in size (Di Virgilio, 1995), thus a likely
mechanism for ATP release is directly through these pores (Suadi-
cani et al., 2006). P2X7 receptors have also been shown to activate
connexin hemichannels (Baroja-Mazo et al., 2012); since, these
hemichannels can also mediate the release of ATP (Lazarowski
et al., 2003; Spray et al., 2006) the participation of the P2X7
receptor in ATP release from bone cells may be indirect. How-
ever, because several of the widely used connexin hemichannel
inhibitors also partly block the P2X7 receptor it is difﬁcult to deter-
mine which of these P2X7-mediated pathways is responsible for
the observed ATP release (Suadicani et al., 2006).
In many cell types, including osteoblasts, endothelial cells, and
ﬁbroblasts, levels of ATP release are increased by external stimuli
such as ﬂuid shear stress and hypoxia (Bodin et al., 1992; Bodin
and Burnstock, 1998; Gerasimovskaya et al., 2002; Genetos et al.,
2005; Orriss et al., 2009). Although not studied here, it is possible
that ATP release from osteoclasts could also be increased follow-
ing exposure to similar external stimuli. This would then have
the potential to inﬂuence the local concentration of ATP (and its
breakdown products) and subsequent purinergic signaling.
In summary, our work indicates that both osteoclasts and
osteoblasts release ATP constitutively by multiple mechanisms
which include efﬂux via the P2X7 receptor. This ﬁnding highlights
further the important role of the P2X7 receptor in the regulation
of bone cell function and extracellular ATP levels.
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